Products
Latest Partnered Companies
Projects

Estimated Cost :
US$1.05 billion
AstraZeneca Invests US$1.05 billion (£1bn) to Construct New R&D Facility
AstraZeneca plans for the construction of state-of-the-art research and development (R&D) facility with an investment of US$1.05 billion (£1bn). The n...

Estimated Cost :
-
Rentschler Biopharma Plans to Open New Manufacturing Center in Boston
Rentschler Biopharma plans to open new manufacturing site that will be an extension

Estimated Cost :
-
Artiva Biotherapeutics to Construct New Research and Manufacturing Center in Republic of Korea
Artiva Biotherapeutics plans to construct new GMP manufacturing center. The facility will be an addition to the Artiva’s continued research and GMP ma...

Estimated Cost :
CHF 850 million
Lonza Constructs Two Next-Generation Mammalian Manufacturing Facilities
Lonza invests US$927 million (CHF850 million) to construct two next-generation mammalian manufacturing facilities
Press Release
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
MEI Pharma, Inc. , a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the grant of inducement stock options for an aggregate of 65,000 shares of the company’s common stock to two new employees. The stock options were granted as a material inducement to each new employee accepting employment with MEI in accordance with Nasdaq Listing Rule 5635(c)(4).
Microsize Launched as Independent Pharma Services Company
Microsize today announced the launch of its business as an independent company to support solubility and bioavailability enhancement via particle reduction technologies including micronization. This announcement marks the completion of the previously announced intent to acquire the North American micronization business from Lonza in Quakertown PA, USA.Microsize is the largest micronization business of its kind in North America.
Akebia Therapeutics Regaining Rights to Vadadustat in the United States, Europe, China and Access Consortium Countries upon Termination of Collaboration and License Agreements with Otsuka
Akebia Therapeutics®, Inc. a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has executed an agreement to terminate the U.S. and ex-U.S. vadadustat Collaboration and License Agreements with Otsuka Pharmaceutical Co., Ltd. (Otsuka). As part of the termination, Otsuka has agreed to pay Akebia a settlement fee of $55 million.
MultiOmic Health and Mesh Bio Partner to Use AI to Develop Precision Medicines and Diagnostics for Chronic Metabolic Disease
MultiOmic Health, an artificial intelligence (AI)-enabled drug discovery company, and Mesh Bio, a digital health startup transforming chronic disease management through predictive analytics, today announce their partnership to conduct an observational clinical study on patients with chronic metabolic disease and increased risk of complications such as chronic kidney disease.
Events
World Congress of Basic and Clinical Pharmacology

International Conference on Advances in Health and Medical Science (ICAHMS)



Articles

Top 12 Analytical Lab Equipments in Pharmaceutical Industry
The analytical lab equipments or instruments are used in analytical applications in pharmaceutical, food-processing laboratories

A Complete Guide on Blister Packaging Machine
Packaging machinery is one of the vital equipment in the pharmaceutical industry, food processing, and chemical

Nanotechnology in Drug Delivery to Eyes, Skin, and Wounds Via Topical Route
One of the most favored courses for administering medications to eyes, skin, and wounds is the topical route. The principle objective for this

An Overview - Active Pharmaceutical Ingredient (API)
Active Pharmaceutical Ingredient (API) is the term used to refer to the biologically active component of a drug product

Next-Generation Biological Therapeutics Discovery & Development
Focus on drug discovery and development has shifted away from small to large, complex molecular entities